Suppr超能文献

溶酶体贮积症:基于干细胞的细胞和基因疗法

Lysosomal storage diseases: Stem cell-based cell- and gene-therapy.

作者信息

Kim Seung U

出版信息

Cell Transplant. 2014 May 21. doi: 10.3727/096368914X681946.

Abstract

Lysosomal storage diseases (LSDs) are caused by inborn genetic defects and most affected babies show pathology in the CNS. LSDs are caused by a specific inherited enzyme deficiency that results in accumulation of substrates in the lysosomes, distension of the organelles and subsequent cellular malfunction. Currently, no effective treatment is available for most of the LSDs, because the blood?brain barrier bars entry of enzyme preparations into the brain. Treatment for LSDs can be divided into those address symptoms or those address cause. At present, successful treatments for the LSDs are enzyme replacement therapy (ERT) and cell therapy. ERT is most successful in Gaucher disease and has been approved for Fabry disease, and mucopolysaccharidosis I (MPS I). In addition, ERT for Pompe disease, MPS II, MPS VI and MPS VII has been planned and awaiting approval for treatment. Limitations in ERT include need for life-long treatment, development of antibodies, and inability to cross blood brain barrier (BBB) resulting in failure to halt disease progression in the brain. Transplantation of hematopoietic stem cells (HSCs), bone marrow stem cells (BMSCs) and umbilical cord blood-derived stem cells (UCBSCs) offer effective but limited efficacy for patients suffering from Krabbe disease, MPS VII and adrenal leukodystrophy but in other LSDs they are ineffective. Intracranial/intracerebral transplantation of genetically modified stem cells as enzyme delivery system could bypass the BBB effectively and ensure release of therapeutically beneficial amount of enzymes to affected CNS lesion sites. For this reason, stem cell-based gene therapy is the most effective treatment for LSDs. In mouse models of LSDs, genetically modified neural stem cells encoding enzyme genes effectively decreased lysosomal storage, reduced pathology and extended life span of animals. Cell-based gene therapies for LSDs bridge the application of ERT and gene therapy and are important direction to pursue in the future.

摘要

溶酶体贮积症(LSDs)由先天性遗传缺陷引起,大多数患病婴儿的中枢神经系统会出现病变。LSDs是由特定的遗传性酶缺乏引起的,这会导致底物在溶酶体中积累,细胞器扩张并随后导致细胞功能障碍。目前,大多数LSDs尚无有效的治疗方法,因为血脑屏障阻碍了酶制剂进入大脑。LSDs的治疗可分为针对症状的治疗和针对病因的治疗。目前,LSDs的成功治疗方法是酶替代疗法(ERT)和细胞疗法。ERT在戈谢病中最为成功,已被批准用于法布里病和黏多糖贮积症I型(MPS I)。此外,针对庞贝病、MPS II、MPS VI和MPS VII的ERT已在计划中,等待批准用于治疗。ERT的局限性包括需要终身治疗、抗体的产生以及无法穿过血脑屏障(BBB),导致无法阻止大脑中的疾病进展。造血干细胞(HSCs)、骨髓干细胞(BMSCs)和脐带血来源的干细胞(UCBSCs)移植对患有克拉伯病、MPS VII和肾上腺脑白质营养不良的患者有效,但疗效有限,而在其他LSDs中则无效。将基因修饰的干细胞作为酶递送系统进行颅内/脑内移植可以有效绕过血脑屏障,并确保向受影响的中枢神经系统病变部位释放治疗有益量的酶。因此,基于干细胞的基因治疗是LSDs最有效的治疗方法。在LSDs的小鼠模型中,编码酶基因的基因修饰神经干细胞有效地减少了溶酶体贮积,减轻了病变并延长了动物的寿命。针对LSDs的基于细胞的基因治疗架起了ERT和基因治疗应用的桥梁,是未来值得追求的重要方向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验